洛赛克、克拉霉素、替硝唑三联疗法治疗愈合的十二指肠球部溃疡患者组织成熟度的观察  

A study on histological maturity of healed duodenal ulcer after triple therapy with omeprazole,clarithromycin and tinidazole

作　　者：李开学[1] 邓联民[1] 刘新民[1] 关弘[2] 陈碧玲[3] 

机构地区：[1]广东省深圳市第二人民医院消化科病理科,518035 [2]广东省深圳市第二人民医院病理科,518035 [3]广东省深圳市第二人民医院消化科,518035

出　　处：《临床内科杂志》2005年第7期463-464,共2页Journal of Clinical Internal Medicine

摘　　要：目的观察洛赛克、克拉霉素、替硝唑三联疗法治疗已愈合的十二指肠球部溃疡(DU)患者“再生”黏膜组织成熟度的变化。方法将64例幽门螺杆菌(HP)感染的活动性DU患者随机分成2组:洛赛克组(36例)应用洛赛克20mg+克拉霉素500mg+替硝唑500mg,每日2次,共用1周;雷尼替丁组(28例)采取雷尼替丁150mg每日2次+阿莫西林500mg每日3次+甲硝唑400mg每日3次,共4周。结果洛赛克组和雷尼替丁组分别有3例和2例失访。洛赛克组和雷尼替丁组溃疡愈合率分别为90.91%(30/33)和69.23%(18/26),P<0.05;洛赛克组和雷尼替丁组HP根除率分别为93.94%(31/33)和65.38%(17/26),P<0.05;再生黏膜组织成熟度洛赛克组30例有22例为良(73.33%),而雷尼替丁组18例中仅6例(33.33%)为良,P<0.01。结论洛赛克、克拉霉素、替硝唑1周三联疗法的HP根除率高,再生黏膜组织成熟度优于含雷尼替丁组方案。Objective To investigate the histological maturity of“regenerated”mucosa in duode-nal ulcer (DU) after triple therapy with omeprazole,clarithromycin and tinidazole.Methods Sixty-fourpatients with Helicobacter pylori (HP) positive active DU were randomly divided into 2 groups:group A(n=36) with omeprazole 20mg,clarithromycin 500mg and tinidazole 500mg (LCT) twice daily for oneweek;group B (n =28) with ranitidine 150mg twicc daily,amoxicillin 500mg thrice daily and metron-idazole 400mg thrice daily (RAM) for 4 weeks.Results Three cases in group A and 2 in group B werelost during follow-up.30 of 33 patients in group A were healed(90.91%) at 4 ~6 weeks after the end oftreatment,18 of 26 patients in group B were healed (69.23%),P<0.05;The eradication rates of HP ingroup A and group B were 93.94%,65.38%,P<0.05;For histological maturity of“regenerated”muco-sa,22 of 30 patients in group A were“good”(73.33%),but only 6 of 18 patients in group B (33.33%),P<0.01.Conclusion After one-week triple therapy with omeprazole,clarithromycin and tini-dazole,the eradication rates of HP were high.The histological maturity of“regenerated”mucosa in patientswith LCTtreatment is preferred to that in patients with RAM treatment.

关 键 词：十二指肠球部溃疡 幽门螺杆菌 

分 类 号：R573.1[医药卫生—消化系统]